MedTrace Logo

Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

NCT00946348 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-07-12

Study results available
· View outcomes & findings →

Summary

The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol. The second aim will serve to further assess the effects of dronabinol on symptoms and medication side effects in this population.

Conditions

  • Schizophrenia
  • Dual Diagnosis
  • Schizoaffective Disorder
  • Psychotic Disorder
  • Cannabis Use Disorder

Interventions

DRUG

Dronabinol

Dronabinol 10 mg or 15 mg

DRUG

Cannabis

Cannabis cigarette

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Indiana University

    collaborator OTHER

  • Columbia University

    collaborator OTHER

  • University of Vermont

    collaborator OTHER

  • University of Massachusetts, Worcester

    collaborator OTHER

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Principal Investigators

  • Alan I Green, MD · Dartmouth-Hitchcock Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00946348 on ClinicalTrials.gov